Abstract
Background: Breast cancer is the most common malignant tumour in women. Radical mastectomy with postoperative radiotherapy is now the standard treatment for locally advanced breast cancer. Intensity-modulated radiotherapy (IMRT) has now been developed, which employs linear accelerators to deliver precise radiation to a tumour while minimizing the dose to surrounding normal tissue. It significantly improves the efficacy of breast cancer treatment. However, there are still some flaws that must be addressed.
Objective: To assess the clinical application of the three-dimensional (3D)-printed chest wall conformal device for breast cancer patients who need to be treated by chest wall intensity modulated radiotherapy (IMRT) after radical mastectomy.
Methods: The 24 patients were divided into three groups. During a computed tomography (CT) scan, patients in the study group were fixed by a 3D-printed chest wall conformal device, nothing in control group A, and a traditional 1-cm thick silica gel compensatory pad on the chest wall in control group B. The parameters of mean Dmax, Dmean, D2%, D50%, D98%, the conformity index (CI), and the homogeneity index (HI) of the planning target volume (PTV) are compared.
Results: The study group had the best dose uniformity (HI = 0.092) and the highest conformation (CI = 0.97), the worst in control group A (HI = 0.304, CI = 0.84). The mean Dmax, Dmean, and D2% of the study group were lower than control groups A and B (p<0.05). The mean D50% was higher than control group B (p<0.05), while the mean D98% was higher than control groups A and B (p<0.05). The mean Dmax, Dmean, D2%, and HI of control group A were higher than control group B (p<0.05), whereas the mean D98% and CI were lower than control group B (p<0.05).
Conclusion: By improving the efficacy of postoperative radiotherapy for breast cancer, using 3D-printed chest wall conformal devices may greatly improve the accuracy of repeating position fixation, increase the dose on the skin surface of the chest wall, optimise the dose distribution of the target area, and thus further reduce tumour recurrence and prolong patients' survival.
[http://dx.doi.org/10.21147/j.issn.1000-9604.2018.01.01] [PMID: 29545714]
[http://dx.doi.org/10.3322/canjclin.52.5.277] [PMID: 12363326]
[http://dx.doi.org/10.5772/intechopen.100315]
[PMID: 21384058]
[http://dx.doi.org/10.1016/j.ijrobp.2011.11.048] [PMID: 22385703]
[http://dx.doi.org/10.1016/j.ijrobp.2009.11.053] [PMID: 20472366]
[http://dx.doi.org/10.1016/j.meddos.2010.01.001] [PMID: 20346646]
[http://dx.doi.org/10.1016/S1350-4487(99)00276-0]
[http://dx.doi.org/10.1016/j.ijom.2012.01.014] [PMID: 22377004]
[http://dx.doi.org/10.1016/S0167-8140(12)71575-X]
[PMID: 25102876]
[PMID: 29862711]
[http://dx.doi.org/10.1056/NEJMoa020989] [PMID: 12393819]
[http://dx.doi.org/10.1016/j.ejmech.2018.04.001] [PMID: 29649739]
[http://dx.doi.org/10.1016/j.apsb.2022.03.021] [PMID: 35865090]
[http://dx.doi.org/10.2174/97898150400741220101]
[http://dx.doi.org/10.1016/S0140-6736(05)67887-7] [PMID: 16360786]
[http://dx.doi.org/10.1088/0031-9155/60/1/L1] [PMID: 25504315]
[http://dx.doi.org/10.1016/0167-8140(94)90063-9] [PMID: 7708953]
[http://dx.doi.org/10.1016/S0360-3016(01)01744-8] [PMID: 11704339]
[http://dx.doi.org/10.1371/journal.pone.0168063] [PMID: 27930717]
[http://dx.doi.org/10.1016/j.meddos.2013.10.005] [PMID: 24355911]